Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

Author： Thompson Melissa  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.16, Iss.6, 2013-06, pp. : 744-755

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An economic evaluation of sevelamer in patients new to dialysis

By Taylor Matthew J.   Elgazzar Heba A.   Chaplin Stephen   Goldsmith David   Molony Donald A.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

JTT-751 for Treatment of Patients with Hyperphosphatemia on Peritoneal Dialysis

By  

Nephron Clin Pract, Vol. 128, Iss. 1-2, 2014-11 ,pp. : 135-140

Karger

Access to resources Recommend Favorite

Hyperphosphatemia and vascular calcification in chronic kidney disease

By Cozzolino Mario   Brancaccio Diego  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 691-692

Future Medicine

Access to resources Recommend Favorite

Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis

By  

Nephron Clin Pract, Vol. 100, Iss. 3, 2005-04 ,pp. : c55-c62

Karger

Access to resources Recommend Favorite

The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia

By Pai A.B.   Smeeding J.E.   Brook R.A.  

Current Medical Research and Opinion, Vol. 20, Iss. 7, 2004-07 ,pp. : 991-999

Informa Healthcare

Access to resources Recommend Favorite